Novo Nordisk nominates two drug industry veterans to strengthen board
By Stine Jacobsen and Louise Rasmussen
COPENHAGEN, Feb 20 (Reuters) - Novo Nordisk NOVOb.CO will nominate drug industry veterans Jan van de Winkel and Ramona Sequeira to its board of directors, the company said on Friday, in the first additions since a shake-up at the Danish obesity drugmaker last year.
Last year, Novo Nordisk and its majority shareholder, the Novo Nordisk Foundation, replaced the drugmaker's CEO and overhauled the board, installing Lars Rebien Sorensen who also chairs the Foundation, as board chairman, giving him a powerful dual role.
Novo Nordisk also confirmed the nomination of Helena Saxon to the board, which was first announced last year. She sits on the board of fashion retailer H&M HMb.ST and was formerly a board member at Swedish drugmaker Sobi SOBIV.ST.
SHARE PRICE PLUNGE OVER TOUGH COMPETITION
The nominations mark a test of Sorensen's promise to strengthen the board's pharmaceutical and commercial expertise after his criticism that the previous board moved too slowly on U.S. market challenges.
Novo Nordisk, maker of Wegovy and Ozempic, faces mounting pressure in the obesity drug market, battling U.S. rival Eli Lilly LLY.N as well as telehealth companies offering cheaper copycat versions of its weight-loss drugs, sending its shares down 49% in the last year.
Novo's shares declined 1.1% by 1243 GMT on Friday.
Van de Winkel, co-founder and CEO of Denmark's Genmab GMAB.CO, was proposed for election at the annual general meeting due on March 26, Novo said in a statement.
At the same time it planned to elect Sequeira, a former head of the Global Portfolio Division of Japan's Takeda Pharmaceutical 4502.T where she worked for 10 years until 2025.
Sequeira previously worked at Eli Lilly in various leadership roles across Canada, Europe and the United States, Novo said.
A former Pfizer executive withdrew his board candidacy in November last year, citing personal grounds.
Related Articles
Will Bank of England Still Cut Rates in 2026? Falling Inflation Favors Loose Monetary Policy, Pound Exchange Rate May Struggle to Sustain Strength.
TradingKey - The outlook for the British Pound in 2026 is undoubtedly one of the most significant focal points for investors in the FX market. Following a structural shift in 2025 characterized by a "low start and high finish," GBP/USD successfully broke out of its two-year trading range and stabilized near 1.35 at year-end, laying the foundation for its performance in 2026.
Why the Yen Falls Further the More It Is Rescued: The Answer Lies in Japan’s Own Structural Contradictions
TradingKey - Entering early 2026, the attention of global investors is once again locked on the Japanese Yen (JPY). Despite the Bank of Japan (BoJ) gradually raising policy rates to a range of 0.5% - 0.75%, marking a definitive end to the era of negative interest rates, the yen continues to trend lower against the U.S. dollar.
Stock Market Crash 2026: What Fed Signals and Economic Data Mean for Investors
TradingKey - The possibility of a stock market crash occurring in 2026 is becoming increasingly likely as investor sentiment continues to decline.
New Fed Chair Warsh Takes Office: Major Shift in Monetary Policy? US Dollar Short-Term Rebound, 2026 Investment Strategy Analysis
TradingKey - At the start of 2026, global financial markets witnessed a major leadership change as U.S. President Trump officially nominated Kevin Warsh as the next Federal Reserve Chair. Pending Senate confirmation, he will succeed Jerome Powell this May to lead the world’s most influential central bank.
